Eli Lilly on Friday crossed the $1 trillion market-cap threshold, becoming the first drugmaker to ever reach that milestone.

New GLP-1 weight-loss drugs may preserve muscle, protect skin, and reduce the risk of "Ozempic face." Experts explain what ...

Lilly’s (LLY) recent climb to reach a $1T market cap will come under scrutiny in the coming days when Novo Nordisk (NVO) ...

A growing number of people are searching for weight loss options that feel manageable in daily life. Many of the current ...

Some research suggests supplements such as berberine, curcumin, resveratrol, fish oil, and probiotics may boost your body's ...

GLP-1 RAs are associated with a 62% reduction in 5-year mortality in colon cancer patients, especially those with high obesity. The study's findings remained significant after adjusting for ...

By 2030, households with GLP-1 users are projected to represent 35% of all food and beverage units sold, the consumer ...

Patients with colon cancer using GLP-1 receptor agonists (the class of drugs behind treatments like Ozempic, Wegovy, and ...

GLP-1 medications may help colon cancer patients live longer by reducing inflammation and improving metabolic health, UC San ...

Studies from Novo Nordisk due early next month will give the strongest indication yet of whether blockbuster GLP-1 drugs - a ...

U.S. researchers are beginning to identify clinical characteristics that distinguish “super responders” to GLP-1 weight-loss ...

NBC News' Anne Thompson joins "Here's the Scoop" co-host Yasmin Vossoughian to talk about why some people are microdosing GLP ...